Association of Ketamine With Psychiatric Symptoms and Implications for Its Therapeutic Use and for Understanding Schizophrenia
K. Beck, Guy Hindley, F. Borgan, Cedric E. Ginestet, R. Mccutcheon, S. Brugger, N. Driesen, M. Ranganathan, D. D’souza, M. Taylor, J. Krystal, O. Howes
JAMA Network Open May 1, 2020 DOI: 10.1001/jamanetworkopen.2020.4693 via Semantic Scholar
Summary
Ketamine administration produces transient psychopathological effects in both healthy volunteers and patients with schizophrenia, with the nature and severity of these effects varying according to experimental factors such as dose, route of administration, and participant characteristics. The meta-analysis quantifies these outcomes, showing that ketamine reliably induces psychotic-like symptoms, dissociation, and cognitive impairments in healthy individuals, while its effects in patients with schizophrenia are more complex and may involve both symptom exacerbation and potential therapeutic benefits depending on the context.
Study at a glance
| Characteristics | Meta-analysis Peer reviewed |
|---|---|
| Population | Healthy volunteers and patients with schizophrenia |
| Keywords | Medicine Psychology |
| Citations | 179 |
| Key finding | Ketamine produces transient psychopathological effects that differ between healthy volunteers and patients with schizophrenia, influenced by experimental factors such as dose and administration route. |
Abstract
This meta-analysis assesses the psychopathological outcomes in healthy volunteers and patients with schizophrenia treated with ketamine and the experimental factors associated with these findings.